academic article

• Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study..  Psychiatric services (Washington, D.C.).  :-. 2016
• Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study..  Schizophrenia bulletin.  41:449-459. 2015
• The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data..  Brain imaging and behavior.  8:153-182. 2014
• The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia..  Neuroinformatics.  11:367-388. 2013
• Cigarette smoking and white matter microstructure in schizophrenia..  Psychiatry research.  201:152-158. 2012
• Antipsychotic dose and diminished neural modulation: a multi-site fMRI study..  Progress in neuro-psychopharmacology & biological psychiatry.  35:473-482. 2011
• Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study..  Schizophrenia bulletin.  37:222-232. 2011
• Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla..  Biological psychiatry.  69:19-27. 2011
• 1H-MRS at 4 tesla in minimally treated early schizophrenia..  Molecular psychiatry.  15:629-636. 2010
• Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  33:2456-2466. 2008
• Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  31:751-756. 2006
• Selective cognitive impairments associated with NMDA receptor blockade in humans..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  30:633-639. 2005
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study..  The American journal of psychiatry.  162:394-396. 2005
• Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels..  Schizophrenia research.  66:31-39. 2004
• Integrated treatment of schizophrenia..  Psychiatric services (Washington, D.C.).  54:1499-1507. 2003
• Reproducibility of 1H-MRS measurements in schizophrenic patients..  Magnetic resonance in medicine.  50:704-707. 2003
• Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia..  The Psychiatric clinics of North America.  26:191-211. 2003
• Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  28:527-529. 2003
• Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial..  JAMA.  289:56-64. 2003
• Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure..  Schizophrenia research.  58:313-321. 2002
• High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia..  The American journal of psychiatry.  159:130-133. 2002
• Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia..  Psychiatry research.  107:135-149. 2001
• Medication treatments for schizophrenia: translating research findings into better outcomes..  Journal of psychiatric practice.  7:260-265. 2001
• Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia..  Seminars in clinical neuropsychiatry.  6:121-130. 2001
• The patient with first episode psychosis..  Journal of psychiatric practice.  7:123-132. 2001
• The psychosocial treatment of schizophrenia: an update..  The American journal of psychiatry.  158:163-175. 2001
• Commentary: can intensive psychosocial treatments make a difference in a time of atypical antipsychotics and managed care?.  Schizophrenia bulletin.  26:141-144. 2000
• A critical review of research on psychosocial treatment of schizophrenia..  Biological psychiatry.  46:1409-1417. 1999
• Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping..  The Journal of nervous and mental disease.  187:72-79. 1999
• Schizophrenia: improving outcome..  Harvard review of psychiatry.  6:229-240. 1999